Pantolev

GERD, PUD & Zollinger-Ellison syndrome.

IV Administer over 2-15 min, either as slow inj or short-term infusion. PUD or GERD 40 mg daily. Zollinger-Ellison syndrome 80 mg once daily or bid. Max: 240 mg daily in divided doses.

Hypersensitivity.

Exclude malignancy in the presence of any alarm symptom (eg, significant unintentional wt loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) & when gastric ulcer is suspected or present. Slightly increased risk of GI infections caused by bacteria (eg, Salmonella, Campylobacter & Clostridium difficile). PPIs are associated w/ very infrequent cases of subacute cutaneous lupus erythematosus; consider stopping treatment if lesions occur especially in sun-exposed skin areas & if accompanied by arthralgia. Increased Chromogranin A (CgA) level may interfere w/ investigations for neuroendocrine tumours; stop treatment for at least 5 days before CgA measurements. Not recommended w/ atazanavir. Discontinue treatment in patients w/ severe liver impairment. Not to be used during pregnancy unless clearly necessary. Decide on whether to continue/discontinue breast-feeding or continue/discontinue therapy taking into account the benefit of breast-feeding to the child & the benefit of therapy to women.

Headache, diarrhoea, dizziness, pruritus, skin rash, flatulence, abdominal pain, rash, eructation, insomnia & hyperglycemia.

Antacids, Antireflux Agents & Antiulcerants

A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

Rx